Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin’s lymphoma
Open Access
- 1 May 2003
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 14 (suppl_1) , i17-i20
- https://doi.org/10.1093/annonc/mdg704
Abstract
1University of Nebraska Medical Center, Omaha, NE, USA; 2Baxter Oncology GmbH, Frankfurt, GermanyKeywords
This publication has 4 references indexed in Scilit:
- The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-RSeminars in Oncology, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's LymphomaJournal of Clinical Oncology, 1999
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995